News - Page 221 - Psychedelic Alpha

Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.

Read more about the article Entheon Biomedical Partners with Divergence Neuro Technologies Inc. for Predictive Biomarker Platform Development

Entheon Biomedical Partners with Divergence Neuro Technologies Inc. for Predictive Biomarker Platform Development

Post published:January 19, 2021
Post category:Press Release

Read more about the article Awakn Strengthens Scientific and Medical Leadership with Appointment of Chief Science Officer and Head of Ketamine Alcohol Use Disorder Practice

Awakn Strengthens Scientific and Medical Leadership with Appointment of Chief Science Officer and Head of Ketamine Alcohol Use Disorder Practice

Post published:January 19, 2021
Post category:Press Release

Read more about the article PharmaTher Signs Exclusive Worldwide License Agreement for Patented Ketamine Formulation Targeting Mental Health, Neurological and Pain Disorders

PharmaTher Signs Exclusive Worldwide License Agreement for Patented Ketamine Formulation Targeting Mental Health, Neurological and Pain Disorders

Post published:January 19, 2021
Post category:Press Release

Read more about the article Havn Life to Support Canadian Counterpart of Veterans’ Organization, Heroic Hearts

Havn Life to Support Canadian Counterpart of Veterans’ Organization, Heroic Hearts

Post published:January 18, 2021
Post category:Press Release

Read more about the article Lobe Sciences Announces Management Changes and New Director

Lobe Sciences Announces Management Changes and New Director

Post published:January 18, 2021
Post category:Press Release

Read more about the article Cybin Announces CDN$20 Million Bought Deal Offering

Cybin Announces CDN$20 Million Bought Deal Offering

Post published:January 18, 2021
Post category:Press Release

Read more about the article Nakul Raval, Researcher at the Neurobiology Research Unit, Copenhagen University Hospital

Nakul Raval, Researcher at the Neurobiology Research Unit, Copenhagen University Hospital

Post published:January 16, 2021
Post category:Interview

Read more about the article Optimi Health Corp. Receives Health Canada Psychedelic Research Exemption and Files Preliminary Prospectus for Initial Public Offering of Units

Optimi Health Corp. Receives Health Canada Psychedelic Research Exemption and Files Preliminary Prospectus for Initial Public Offering of Units

Post published:January 15, 2021
Post category:Press Release

Read more about the article Psychedelic Bulletin: Psychedelics Companies Embrace Tech; MindMed to Study LSD Microdosing; UFC Eyes Psychedelics

Psychedelic Bulletin: Psychedelics Companies Embrace Tech; MindMed to Study LSD Microdosing; UFC Eyes Psychedelics

Post published:January 15, 2021
Post category:Psychedelic Bulletin

Read more about the article Awakn Life Sciences Appoints CRO to Conduct Phase II Study of MDMA as a Treatment for Alcohol Use Disorder

Awakn Life Sciences Appoints CRO to Conduct Phase II Study of MDMA as a Treatment for Alcohol Use Disorder

Post published:January 15, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.